![Alliance for Regenerative Medicine Logo](https://alliancerm.org/wp-content/uploads/2018/05/arm_logo_white_text.png)
Media Contact:
Stephen Majors
Head of Global Communications
smajors@alliancerm.org
Washington, DC
The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. The committee and board are subject to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.
Washington, DC
Washington, DC
Washington, DC
The Alliance for Regenerative Medicine (ARM) applauds the Centers for Medicare and Medicaid Services’ (CMS) decision to finalize a new diagnosis-related group (DRG) for chimeric antigen receptor T cell (CAR-T) therapies in their FY21 Inpatient Prospective Payment System (IPPS) rule. This is a crucial step forward for patient access to life-changing therapies, and the result of multi-year collaboration among ARM, its members, regulators, and a diverse group of other stakeholders.